Metabolism and disposition of lesinurad, a uric acid reabsorption inhibitor, in humans
Sign Up to like & getrecommendations! Published in 2019 at "Xenobiotica"
DOI: 10.1080/00498254.2018.1504257
Abstract: Abstract The objectives of this study were to determine the absolute bioavailability of lesinurad and to characterized its disposition in humans. The oral bioavailability assessment was performed using a clinical design of simultaneous dosing of… read more here.
Keywords: disposition; lesinurad uric; metabolism disposition; disposition lesinurad ... See more keywords
An in vivo evaluation of the ontogeny of stereoselective fluoxetine metabolism and disposition in lambs from birth to one year of age
Sign Up to like & getrecommendations! Published in 2019 at "Xenobiotica"
DOI: 10.1080/00498254.2018.1563922
Abstract: Abstract 1. The objective was to determine the ontogeny of stereoselective fluoxetine (FX) disposition in postnatal sheep from newborn to adulthood. 2. Catheters were implanted in a carotid artery and jugular vein. FX was administered… read more here.
Keywords: disposition; metabolism; metabolism disposition; stereoselective fluoxetine ... See more keywords
Metabolism and disposition of the SGLT2 inhibitor bexagliflozin in rats, monkeys and humans
Sign Up to like & getrecommendations! Published in 2019 at "Xenobiotica"
DOI: 10.1080/00498254.2019.1654634
Abstract: Abstract Bexagliflozin is a C-aryl glucoside inhibitor of human sodium-glucose linked transporter 2 (SGLT2) that undergoes oxidation and glucuronidation to form six principal metabolites in humans. In vitro metabolism by human liver microsomes and recombinant… read more here.
Keywords: monkeys humans; inhibitor; metabolism; bexagliflozin ... See more keywords
Metabolism and disposition in rats, dogs, and humans of erdafitinib, an orally administered potent pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor
Sign Up to like & getrecommendations! Published in 2020 at "Xenobiotica"
DOI: 10.1080/00498254.2020.1821123
Abstract: Abstract This article describes in vivo biotransformation and disposition of erdafitinib following single oral dose of 3H-erdafitinib and 14C-erdafitinib to intact and bile duct-cannulated (BC) rats (4 mg/kg), 3H-erdafitinib to intact dogs (0.25 mg/kg), and 14C-erdafitinib to… read more here.
Keywords: disposition rats; erdafitinib major; metabolism disposition; rats dogs ... See more keywords